First Time Loading...

BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 25.1 USD 0.88%
Updated: Apr 29, 2024

Wall Street
Price Targets

BBIO Price Targets Summary
BridgeBio Pharma Inc

Wall Street analysts forecast BBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BBIO is 49.98 USD with a low forecast of 33.33 USD and a high forecast of 73.5 USD.

Lowest
Price Target
33.33 USD
33% Upside
Average
Price Target
49.98 USD
99% Upside
Highest
Price Target
73.5 USD
193% Upside
BridgeBio Pharma Inc Competitors:
Price Targets
688276
Changchun BCHT Biotechnology Co
75% Upside
SNPX
Synaptogenix Inc
209% Upside
MRNA
Moderna Inc
22% Upside
CYTH
Cyclo Therapeutics Inc
194% Upside
KOD
Kodiak Sciences Inc
29% Upside
ADCT
ADC Therapeutics SA
140% Upside
BLRX
BioLine RX Ltd
82% Downside
2256
Abbisko Cayman Ltd
170% Upside

Revenue
Forecast

Revenue Estimate
BridgeBio Pharma Inc

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 3 years is 314%.

N/A
Past Growth
314%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Operating Income
Forecast

Operating Income Estimate
BridgeBio Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
BridgeBio Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BBIO's stock price target?
Price Target
49.98 USD

According to Wall Street analysts, the average 1-year price target for BBIO is 49.98 USD with a low forecast of 33.33 USD and a high forecast of 73.5 USD.

What is BridgeBio Pharma Inc's Revenue forecast?
Projected CAGR
314%

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 3 years is 314%.